Signs to Watch: Tysabri and PML Risk Over Time

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Exposure Concerns

If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) can be critical for timely intervention. The medical community has long recognized the importance of balancing therapeutic benefits with potential risks, and this page outlines who may need closer monitoring and what symptoms to watch for over the course of treatment.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and post-marketing surveillance. PML is caused by reactivation of the JC virus, which typically remains dormant in individuals with healthy immune systems. Tysabri works by binding to alpha-4 integrins on immune cells, preventing their migration into the central nervous system. This mechanism, while effective for reducing inflammation in multiple sclerosis, also impairs immune surveillance in the brain, allowing JC virus to replicate unchecked.

Risk Factors and Clinical Presentation of PML

The FDA label identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration—especially beyond two years—further elevates that risk. Prior use of immunosuppressive medications compounds the danger by further weakening the immune system. Clinical presentation of PML can be subtle initially, with symptoms that may mimic a multiple sclerosis relapse. Common early signs include progressive weakness on one side of the body, clumsiness, visual disturbances, and changes in thinking or memory. The FDA label advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically involves brain MRI and detection of JC virus DNA in cerebrospinal fluid. Without prompt intervention, PML progresses rapidly and is often fatal or leads to permanent disability.

Timeline and Consequences of Tysabri-Associated PML

The timeline between Tysabri exposure and PML onset varies. In clinical trials, PML occurred in three patients: two with multiple sclerosis who had received Tysabri for a median of 120 weeks, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data from the FDA Adverse Event Reporting System (FAERS) show that adverse events associated with Tysabri are numerous, with fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly quantify PML incidence, they underscore the drug's significant side-effect profile. For patients who develop PML, the consequences are devastating. The boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often experience permanent neurological deficits, including cognitive impairment, motor dysfunction, and vision loss.

Legal Considerations for Tysabri-Related PML Claims

Given the severity of this outcome, the adequacy of warnings provided to patients and healthcare providers is a critical concern. The FDA requires Tysabri to be distributed through a restricted program called TOUCH, which mandates prescriber and patient education about PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients fully understand the magnitude of risk, especially when considering the interplay of risk factors such as antibody status and treatment duration. From a legal perspective, individuals who have developed PML after Tysabri treatment may seek compensation through product liability claims. An attorney specializing in Tysabri-related PML cases can help evaluate whether the drug's manufacturer provided adequate warnings and whether the patient's specific risk factors were properly assessed. Key considerations include the timing of PML diagnosis relative to treatment initiation, the presence of anti-JCV antibodies, and any prior use of immunosuppressants. The FDA label explicitly states that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Failure to adequately weigh these risks could form the basis of a legal claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it cause PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug works by blocking immune cells from entering the brain, which can allow the JC virus to replicate unchecked (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The FDA identifies three key risk factors: presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the early symptoms of PML?

Early symptoms can include progressive weakness on one side of the body, clumsiness, visual disturbances, and changes in thinking or memory. These may mimic a multiple sclerosis relapse, so prompt evaluation is critical (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed?

Diagnosis typically involves brain MRI and detection of JC virus DNA in cerebrospinal fluid. Immediate discontinuation of Tysabri is recommended at the first sign of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit if I developed PML after taking Tysabri?

Yes, individuals who developed PML after Tysabri treatment may pursue product liability claims, particularly if the manufacturer failed to provide adequate warnings or properly assess risk factors. An attorney specializing in Tysabri-related PML cases can help evaluate your claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.